BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 21300055)

  • 1. Quantitative study of the antagonistic effect of (-)-cis-1-Methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol (SB-612111) on nociceptin/orphanin FQ-mediated potassium channel activation in rat periaqueductal gray slices.
    Liao YY; Jiang F; Chiou LC
    Eur J Pharmacol; 2011 Apr; 657(1-3):84-8. PubMed ID: 21300055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1-Benzyl-N-[3-[spiroisobenzofuran-1(3H),4'-piperidin-1-yl]propyl]pyrrolidine-2-carboxamide (Compound 24) antagonizes NOP receptor-mediated potassium channel activation in rat periaqueductal gray slices.
    Liao YY; Trapella C; Chiou LC
    Eur J Pharmacol; 2009 Mar; 606(1-3):84-9. PubMed ID: 19374842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Nphe(1)]N/OFQ-(1-13)-NH(2) is a competitive and selective antagonist at nociceptin/orphanin FQ receptors mediating K(+) channel activation in rat periaqueductal gray slices.
    Chiou LC; Fan SH; Guerrini R; Caló G
    Neuropharmacology; 2002 Feb; 42(2):246-52. PubMed ID: 11804621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vitro studies.
    Spagnolo B; Carrà G; Fantin M; Fischetti C; Hebbes C; McDonald J; Barnes TA; Rizzi A; Trapella C; Fanton G; Morari M; Lambert DG; Regoli D; Calò G
    J Pharmacol Exp Ther; 2007 Jun; 321(3):961-7. PubMed ID: 17329552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative study of [(pF)Phe4,Arg14,Lys15]nociceptin/orphanin FQ-NH2 (UFP-102) at NOP receptors in rat periaqueductal gray slices.
    Kuo CJ; Liao YY; Guerrini R; Calo' G; Chiou LC
    Eur J Pharmacol; 2008 Jan; 579(1-3):110-5. PubMed ID: 17976580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Nphe1,Arg14,Lys15]N/OFQ-NH2 is a competitive antagonist of NOP receptors in the periaqueductal gray.
    Chiou LC; Liao YY; Guerrini R; Calo' G
    Eur J Pharmacol; 2005 May; 515(1-3):47-53. PubMed ID: 15896734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ro 64-6198 [(1S,3aS)-8-(2,3,3a,4,5,6-Hexahydro-1H-phenalen-1-yl)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one] acts differently from nociceptin/orphanin FQ in rat periaqueductal gray slices.
    Chiou LC; Chuang KC; Wichmann J; Adam G
    J Pharmacol Exp Ther; 2004 Nov; 311(2):645-51. PubMed ID: 15254141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional heterogeneity of nociceptin/orphanin FQ receptors revealed by (+)-5a Compound and Ro 64-6198 in rat periaqueductal grey slices.
    Liao YY; Teng SF; Lin LC; Kolczewski S; Prinssen EP; Lee LJ; Ho IK; Chiou LC
    Int J Neuropsychopharmacol; 2011 Aug; 14(7):977-89. PubMed ID: 21029514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence.
    Witkin JM; Statnick MA; Rorick-Kehn LM; Pintar JE; Ansonoff M; Chen Y; Tucker RC; Ciccocioppo R
    Pharmacol Ther; 2014 Mar; 141(3):283-99. PubMed ID: 24189487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological characterization of nociceptin/orphanin FQ receptors, a novel opioid receptor family, in the midbrain periaqueductal gray.
    Chiou LC; Fan SH; Chuang KC; Liao YY; Lee SZ
    Ann N Y Acad Sci; 2004 Oct; 1025():398-403. PubMed ID: 15542742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vivo studies.
    Rizzi A; Gavioli EC; Marzola G; Spagnolo B; Zucchini S; Ciccocioppo R; Trapella C; Regoli D; Calò G
    J Pharmacol Exp Ther; 2007 Jun; 321(3):968-74. PubMed ID: 17329551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nociceptin/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin/orphanin FQ/mu-opioid receptor agonists.
    Khroyan TV; Polgar WE; Jiang F; Zaveri NT; Toll L
    J Pharmacol Exp Ther; 2009 Dec; 331(3):946-53. PubMed ID: 19713488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockade of the nociceptin/orphanin FQ/NOP receptor system in the rat ventrolateral periaqueductal gray potentiates DAMGO analgesia.
    Scoto GM; Aricò G; Ronsisvalle S; Parenti C
    Peptides; 2007 Jul; 28(7):1441-6. PubMed ID: 17628212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CompB (J-113397), selectively and competitively antagonizes nociceptin activation of inwardly rectifying K(+) channels in rat periaqueductal gray slices.
    Chiou LC; Fan SH
    Neuropharmacology; 2002 Jun; 42(7):987-92. PubMed ID: 12069909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative study of [Tyr10]nociceptin/orphanin FQ (1-11) at NOP receptors in rat periaqueductal gray and expressed NOP receptors in HEK293 cells.
    Liao YY; Lee CW; Ho IK; Chiou LC
    Life Sci; 2012 Feb; 90(7-8):306-12. PubMed ID: 22213115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Phe1psi(CH2-NH)Gly2]nociceptin-(1 - 13)-NH2 activation of an inward rectifier as a partial agonist of ORL1 receptors in rat periaqueductal gray.
    Chiou LC
    Br J Pharmacol; 1999 Sep; 128(1):103-7. PubMed ID: 10498840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effects of nociceptin/orphanin FQ (NOP) receptor agonists in acute versus chronic pain: studies with bifunctional NOP/μ receptor agonists in the sciatic nerve ligation chronic pain model in mice.
    Khroyan TV; Polgar WE; Orduna J; Montenegro J; Jiang F; Zaveri NT; Toll L
    J Pharmacol Exp Ther; 2011 Nov; 339(2):687-93. PubMed ID: 21859931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The functional antiopioid action of the ventrolateral periaqueductal gray nociceptin/orphanin FQ and nociceptin receptor system underlies DAMGO analgesic tolerance.
    Parenti C; Scoto GM
    Pharmacology; 2010; 86(3):138-44. PubMed ID: 20689345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease.
    Arcuri L; Viaro R; Bido S; Longo F; Calcagno M; Fernagut PO; Zaveri NT; Calò G; Bezard E; Morari M
    Neurobiol Dis; 2016 May; 89():55-64. PubMed ID: 26804029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential antagonism by naloxone benzoylhydrazone of the activation of inward rectifying K+ channels by nociceptin and a mu-opioid in rat periaqueductal grey slices.
    Chiou LC
    Naunyn Schmiedebergs Arch Pharmacol; 2001 Jun; 363(6):583-9. PubMed ID: 11414652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.